MN-REACH will provide the initial investment and resources to nurture innovators to develop high-priority technologies within the NIH's mission by providing:

  1. Infrastructure for identifying the most promising technologies;
  2. Funding for product definition studies (e.g. feasibility studies, prototype development, or proof-of-concept studies);
  3. Coordinated access to expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and;
  4. Skills development and hands-on experience in understanding strategic steps and key stakeholders along a commercialization path in order to reach the desired patient population (e.g. industry collaboration, licensing, entrepreneurship).


Through nine funding cycles over three years, MN-REACH will offer grant opportunities, up to $150,000 per project, for health care technologies (devices, therapeutics, diagnostics, etc.) that (1) address an unmet medical need; and, (2) are within a few actionable steps of commercialization.  Some examples include: cancer therapies which can be brought rapidly into clinical trials; medical devices related to treatments of brain conditions (neuromodulation); and, therapeutics which are closer to commercialization.  

Applicants can request funding for anything that will make the technology more attractive to the private sector, including but not limited to small molecule drugs, therapeutic devices, mobile health applications, cell-based therapies, diagnostic devices, and combination drug/device products.

Grants are open to any University of Minnesota faculty or researcher who meets the University’s Principle Investigator (PI) eligibility requirement. See Regents' Policy. Partnerships with private companies, community organizations, faculty start-up companies, other Universities and student projects are allowable so long as the Intellectual Property (IP) is wholly or partially-owned by the University of Minnesota and the MN-REACH funding is awarded to and managed through an eligible University PI. 


Cycle 1: Awarded November 2015
Cycle 2: Awarded January 2016
Cycle 3: Awarded July 2016
Cycle 4: Awarded January 2017
Cycle 5: Awarded July 2017
Cycle 6: Awarded December 2017

Schedule is subject to change.